Replidyne, Inc. (Nasdaq: RDYN) 49% LOWER; Replidyne and Forest Laboratories said the FDA has issued a non-approvable letter for Replidyne's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE